Lady_sasa___的个人主页 - 老虎社区

Lady_sasa___

Lady_sasa___

暂无个人介绍

IP属地：0

42关注

1粉丝

3主题

0勋章

2023-03-13

z我？看，： ..........................

南向资金3月10日净卖出美图公司1398.70万股连续3日减持

2023-01-24

ooooo藕哦哦哦哦咯咯欧呕心@玲儿小盯裆在

抱歉，原内容已删除

2023-01-24

这篇文章不错，转发给大家看看

抱歉，原内容已删除

2022-12-06

D西安车站z swazzzsz

抱歉，原内容已删除

2022-11-09

$微盟集团(02013)$ 呢急急急KO我尽力了解u还敢不敢个，

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3542166693292278,"uuid":"3542166693292278","gmtCreate":1579072671177,"gmtModify":1579072742751,"name":"Lady_sasa___","pinyin":"ladysasaladysasa","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":42,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":3,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"0","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":627794284,"gmtCreate":1678679738148,"gmtModify":1678679740107,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"z我？看，：&nbsp; &nbsp;..........................","listText":"z我？看，：&nbsp; &nbsp;..........................","text":"z我？看，： ..........................","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/627794284","repostId":"2319088945","repostType":2,"repost":{"id":"2319088945","pubTimestamp":1678671118,"share":"https://www.laohu8.com/m/news/2319088945?lang=&edition=full","pubTime":"2023-03-13 09:31","market":"hk","language":"zh","title":"南向资金3月10日净卖出美图公司1398.70万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2319088945","media":"自选股智能写手","summary":"3月10日，南向资金减持美图公司1398.70万股连续3日减持。截止当日收盘，港股通共持有美图公司83114.10万股，占流通股18.69%。美图公司近5个交易日下跌7.00%，港股通累计减持2142.45万股；近20个交易日上涨10.71%，港股通累计增持11133.60万股。","content":"<html><body><article><p>3月10日，南向资金减持<a href=\"https://laohu8.com/S/01357\">美图公司</a>1398.70万股连续3日减持。截止当日收盘，港股通共持有美图公司83114.10万股，占流通股18.69%。港股通减持金额前五个股分别为<a href=\"https://laohu8.com/S/601939\">建设银行</a>、<a href=\"https://laohu8.com/S/02269\">药明生物</a>、<a href=\"https://laohu8.com/S/01211\">比亚迪股份</a>、<a href=\"https://laohu8.com/S/01548\">金斯瑞生物科技</a>、<a href=\"https://laohu8.com/S/02162\">康诺亚-B</a>。</p><p>美图公司近5个交易日下跌7.00%，港股通累计减持2142.45万股；近20个交易日上涨10.71%，港股通累计增持11133.60万股。</p><p>|3月10日港股通（深）十大成交榜|||#|股票简称|买入及卖出金额|净流入|#|<a href=\"https://laohu8.com/S/00700\">腾讯控股</a>|25.68亿|-6.50亿|#|<a href=\"https://laohu8.com/S/03690\">美团-W</a>|20.09亿|9.50亿|#|<a href=\"https://laohu8.com/S/CHL\">中国移动</a>|9.89亿|0.29亿|#|<a href=\"https://laohu8.com/S/02015\">理想汽车-W</a>|9.79亿|5.41亿|#|<a href=\"https://laohu8.com/S/01797\">新东方在线</a>|5.47亿|0.78亿|#|<a href=\"https://laohu8.com/S/600050\">中国联通</a>|4.98亿|0.20亿|#|<a href=\"https://laohu8.com/S/09868\">小鹏汽车-W</a>|4.63亿|3.45亿|#|药明生物|4.40亿|0.32亿|#|<a href=\"https://laohu8.com/S/00883\">中国海洋石油</a>|4.39亿|-0.40亿|#|<a href=\"https://laohu8.com/S/01024\">快手-W</a>|4.28亿|1.27亿|</p><p>|3月10日港股通（沪）十大成交榜|||#|股票简称|买入及卖出金额|净流入|#|腾讯控股|31.35亿|7.16亿|#|美团-W|19.53亿|-6.25亿|#|<a href=\"https://laohu8.com/S/600941\">中国移动</a>|9.78亿|1.69亿|#|中国海洋石油|6.37亿|0.46亿|#|<a href=\"https://laohu8.com/S/00762\">中国联通</a>|6.01亿|-0.91亿|#|<a href=\"https://laohu8.com/S/01810\">小米集团-W</a>|5.83亿|-2.50亿|#|<a href=\"https://laohu8.com/S/CHA\">中国电信</a>|5.68亿|0.64亿|#|药明生物|5.28亿|0.40亿|#|<a href=\"https://laohu8.com/S/002594\">比亚迪</a>股份|5.05亿|-1.17亿|#|<a href=\"https://laohu8.com/S/LI\">理想汽车</a>-W|5.04亿|-1.40亿|</p><p>（以上内容为自选股<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>机器写手Money Call完成，仅作为用户看盘参考，不能作为买入依据。）</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>南向资金3月10日净卖出美图公司1398.70万股 连续3日减持</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n南向资金3月10日净卖出美图公司1398.70万股 连续3日减持\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-13 09:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023031309355482bad8ec&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月10日，南向资金减持美图公司1398.70万股连续3日减持。截止当日收盘，港股通共持有美图公司83114.10万股，占流通股18.69%。港股通减持金额前五个股分别为建设银行、药明生物、比亚迪股份、金斯瑞生物科技、康诺亚-B。美图公司近5个交易日下跌7.00%，港股通累计减持2142.45万股；近20个交易日上涨10.71%，港股通累计增持11133.60万股。|3月10日港股通（深）十大成交...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023031309355482bad8ec&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1609":"ChatGPT概念","01357":"美图公司","BK1095":"互动媒体与服务"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023031309355482bad8ec&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2319088945","content_text":"3月10日，南向资金减持美图公司1398.70万股连续3日减持。截止当日收盘，港股通共持有美图公司83114.10万股，占流通股18.69%。港股通减持金额前五个股分别为建设银行、药明生物、比亚迪股份、金斯瑞生物科技、康诺亚-B。美图公司近5个交易日下跌7.00%，港股通累计减持2142.45万股；近20个交易日上涨10.71%，港股通累计增持11133.60万股。|3月10日港股通（深）十大成交榜|||#|股票简称|买入及卖出金额|净流入|#|腾讯控股|25.68亿|-6.50亿|#|美团-W|20.09亿|9.50亿|#|中国移动|9.89亿|0.29亿|#|理想汽车-W|9.79亿|5.41亿|#|新东方在线|5.47亿|0.78亿|#|中国联通|4.98亿|0.20亿|#|小鹏汽车-W|4.63亿|3.45亿|#|药明生物|4.40亿|0.32亿|#|中国海洋石油|4.39亿|-0.40亿|#|快手-W|4.28亿|1.27亿||3月10日港股通（沪）十大成交榜|||#|股票简称|买入及卖出金额|净流入|#|腾讯控股|31.35亿|7.16亿|#|美团-W|19.53亿|-6.25亿|#|中国移动|9.78亿|1.69亿|#|中国海洋石油|6.37亿|0.46亿|#|中国联通|6.01亿|-0.91亿|#|小米集团-W|5.83亿|-2.50亿|#|中国电信|5.68亿|0.64亿|#|药明生物|5.28亿|0.40亿|#|比亚迪股份|5.05亿|-1.17亿|#|理想汽车-W|5.04亿|-1.40亿|（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不能作为买入依据。）","news_type":1},"isVote":1,"tweetType":1,"viewCount":552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":626553770,"gmtCreate":1674559482890,"gmtModify":1674559484953,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ooooo藕哦哦哦哦咯咯欧呕心<a href=\"https://laohu8.com/U/3499558656285424\">@玲儿小盯裆 &nbsp;</a>在","listText":"ooooo藕哦哦哦哦咯咯欧呕心<a href=\"https://laohu8.com/U/3499558656285424\">@玲儿小盯裆 &nbsp;</a>在","text":"ooooo藕哦哦哦哦咯咯欧呕心@玲儿小盯裆 在","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/626553770","repostId":"2305516683","repostType":2,"isVote":1,"tweetType":1,"viewCount":615,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":626553557,"gmtCreate":1674559338579,"gmtModify":1674559342695,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/626553557","repostId":"2305516683","repostType":2,"isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":629355728,"gmtCreate":1670299134065,"gmtModify":1670300329655,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"D西安车站z swazzzsz","listText":"D西安车站z swazzzsz","text":"D西安车站z swazzzsz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629355728","repostId":"2267530933","repostType":2,"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":664690680,"gmtCreate":1667976886740,"gmtModify":1667977436688,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02013\">$微盟集团(02013)$ &nbsp;</a> 呢急急急KO我尽力了解u还敢不敢个，","listText":"<a href=\"https://laohu8.com/S/02013\">$微盟集团(02013)$ &nbsp;</a> 呢急急急KO我尽力了解u还敢不敢个，","text":"$微盟集团(02013)$ 呢急急急KO我尽力了解u还敢不敢个，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/664690680","isVote":1,"tweetType":1,"viewCount":758,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":627794284,"gmtCreate":1678679738148,"gmtModify":1678679740107,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"z我？看，：&nbsp; &nbsp;..........................","listText":"z我？看，：&nbsp; &nbsp;..........................","text":"z我？看，： ..........................","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/627794284","repostId":"2319088945","repostType":2,"isVote":1,"tweetType":1,"viewCount":552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":626553770,"gmtCreate":1674559482890,"gmtModify":1674559484953,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ooooo藕哦哦哦哦咯咯欧呕心<a href=\"https://laohu8.com/U/3499558656285424\">@玲儿小盯裆 &nbsp;</a>在","listText":"ooooo藕哦哦哦哦咯咯欧呕心<a href=\"https://laohu8.com/U/3499558656285424\">@玲儿小盯裆 &nbsp;</a>在","text":"ooooo藕哦哦哦哦咯咯欧呕心@玲儿小盯裆 在","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/626553770","repostId":"2305516683","repostType":2,"isVote":1,"tweetType":1,"viewCount":615,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":626553557,"gmtCreate":1674559338579,"gmtModify":1674559342695,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/626553557","repostId":"2305516683","repostType":2,"repost":{"id":"2305516683","pubTimestamp":1674508711,"share":"https://www.laohu8.com/m/news/2305516683?lang=&edition=full","pubTime":"2023-01-24 05:18","market":"us","language":"en","title":"NBT Bancorp Non-GAAP EPS of $0.86 misses by $0.05, revenue of $133.87M beats by $0.23M","url":"https://stock-news.laohu8.com/highlight/detail?id=2305516683","media":"seekingalpha","summary":"NBT Bancorp press release  (NASDAQ:NBTB): Q4  Non-GAAP EPS of $0.86  misses by $0.05.\nRevenue of $13","content":"<html><body><ul>\n<li>NBT Bancorp press release  (<span>NASDAQ:NBTB</span>): Q4  Non-GAAP EPS of $0.86 <font color=\"red\"> misses by $0.05</font>.</li>\n<li>Revenue of $133.87M (+6.0% Y/Y) <font color=\"green\"> beats by $0.23M</font>.</li>\n</ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NBT Bancorp Non-GAAP EPS of $0.86 misses by $0.05, revenue of $133.87M beats by $0.23M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNBT Bancorp Non-GAAP EPS of $0.86 misses by $0.05, revenue of $133.87M beats by $0.23M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-24 05:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3926888-nbt-bancorp-non-gaap-eps-of-0_86-misses-0_05-revenue-of-133_87m-beats-0_23m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NBT Bancorp press release  (NASDAQ:NBTB): Q4  Non-GAAP EPS of $0.86  misses by $0.05.\nRevenue of $133.87M (+6.0% Y/Y)  beats by $0.23M.</p>\n\n<a href=\"https://seekingalpha.com/news/3926888-nbt-bancorp-non-gaap-eps-of-0_86-misses-0_05-revenue-of-133_87m-beats-0_23m\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SQQQ":"纳指三倍做空ETF","QQQ":"纳指100ETF","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","NBTB":"NBT Bancorp Inc","QLD":"纳指两倍做多ETF","BK4211":"区域性银行"},"source_url":"https://seekingalpha.com/news/3926888-nbt-bancorp-non-gaap-eps-of-0_86-misses-0_05-revenue-of-133_87m-beats-0_23m","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2305516683","content_text":"NBT Bancorp press release  (NASDAQ:NBTB): Q4  Non-GAAP EPS of $0.86  misses by $0.05.\nRevenue of $133.87M (+6.0% Y/Y)  beats by $0.23M.","news_type":1},"isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":629355728,"gmtCreate":1670299134065,"gmtModify":1670300329655,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"D西安车站z swazzzsz","listText":"D西安车站z swazzzsz","text":"D西安车站z swazzzsz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629355728","repostId":"2267530933","repostType":2,"repost":{"id":"2267530933","pubTimestamp":1663073828,"share":"https://www.laohu8.com/m/news/2267530933?lang=&edition=full","pubTime":"2022-09-13 20:57","market":"us","language":"en","title":"Cardiff Oncology falls 19% on plans to drop prostate cancer programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2267530933","media":"seekingalpha","summary":"The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading ","content":"<html><body> <p>The shares of clinical-stage biotech Cardiff Oncology (<span>NASDAQ:CRDF</span>) <span>shed ~19% </span>in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies in metastatic castrate-resistant prostate cancer (mCRPC).</p> <p>The decision followed<span> a strategic review of clinical data and the current and projected therapeutic landscape for the indication, the company said, noting plans to reprioritize efforts on metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC).</span></p> <p>Given the unmet medical need and market opportunity in mCRC and mPDAC and the company’s results for the indications, “we will be focusing our resources on these programs and will not independently fund future clinical activities in prostate cancer,” Chief Executive Mark Erlander said.</p> <p>CRDF also announced plans to start a randomized Phase 2 trial for its lead asset Onvansertib in patients with KRAS-mutated mCRC in a second-line setup. The trial designed to test onvansertib in combination with standard-of-care (SoC) FOLFIRI/bevacizumab is expected to generate topline data in 2H 2024.</p> <p>Highlighting initial data from the Phase 2 trial in second-line mPDAC, CRDF said that 4 out of 5 evaluable patients in the ongoing open-label study achieved disease control and remained on treatment as of the data cutoff date. The fifth evaluable patient has discontinued the study due to progressive disease.</p> <p>The study was designed to evaluate onvansertib in combination with nanoliposomal irinotecan and 5-FU in second-line metastatic PDAC. More data from the study are expected in Q2 or Q3 2023.</p> <p>Updating on its liquidity level, CRDF said that its current cash resources would be adequate to fund operations into 2025.</p> <p>The pipeline update comes a day after CRDF added ~11% Monday in reaction to the company’s presentation at the ESMO Congress 2022 on Phase 1b/2 data for Onvansertib in patients with KRAS-mutated mCRC in a second-line setup.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardiff Oncology falls 19% on plans to drop prostate cancer programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardiff Oncology falls 19% on plans to drop prostate cancer programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-13 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3882308-crdf-stock-falls-on-plans-to-drop-prostate-cancer-programs><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies ...</p>\n\n<a href=\"https://seekingalpha.com/news/3882308-crdf-stock-falls-on-plans-to-drop-prostate-cancer-programs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRDF":"Cardiff Oncology, Inc.","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3882308-crdf-stock-falls-on-plans-to-drop-prostate-cancer-programs","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2267530933","content_text":"The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies in metastatic castrate-resistant prostate cancer (mCRPC). The decision followed a strategic review of clinical data and the current and projected therapeutic landscape for the indication, the company said, noting plans to reprioritize efforts on metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). Given the unmet medical need and market opportunity in mCRC and mPDAC and the company’s results for the indications, “we will be focusing our resources on these programs and will not independently fund future clinical activities in prostate cancer,” Chief Executive Mark Erlander said. CRDF also announced plans to start a randomized Phase 2 trial for its lead asset Onvansertib in patients with KRAS-mutated mCRC in a second-line setup. The trial designed to test onvansertib in combination with standard-of-care (SoC) FOLFIRI/bevacizumab is expected to generate topline data in 2H 2024. Highlighting initial data from the Phase 2 trial in second-line mPDAC, CRDF said that 4 out of 5 evaluable patients in the ongoing open-label study achieved disease control and remained on treatment as of the data cutoff date. The fifth evaluable patient has discontinued the study due to progressive disease. The study was designed to evaluate onvansertib in combination with nanoliposomal irinotecan and 5-FU in second-line metastatic PDAC. More data from the study are expected in Q2 or Q3 2023. Updating on its liquidity level, CRDF said that its current cash resources would be adequate to fund operations into 2025. The pipeline update comes a day after CRDF added ~11% Monday in reaction to the company’s presentation at the ESMO Congress 2022 on Phase 1b/2 data for Onvansertib in patients with KRAS-mutated mCRC in a second-line setup.","news_type":1},"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":664690680,"gmtCreate":1667976886740,"gmtModify":1667977436688,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02013\">$微盟集团(02013)$ &nbsp;</a> 呢急急急KO我尽力了解u还敢不敢个，","listText":"<a href=\"https://laohu8.com/S/02013\">$微盟集团(02013)$ &nbsp;</a> 呢急急急KO我尽力了解u还敢不敢个，","text":"$微盟集团(02013)$ 呢急急急KO我尽力了解u还敢不敢个，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/664690680","isVote":1,"tweetType":1,"viewCount":758,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}